INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA

Ludwig, H, Weisel, K, Petrucci, MT, Leleu, X, Cafro, AM, Kropff, M, Greil, R, Zojer, N, Dummler, T, Kruschinski, A, Riecke, K, Foa, R, Yakoub-Agha, I, Engelhardt, M HAEMATOLOGICA. 2014, 99: 115-116.

AN INTERNATIONAL, MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF NEUTROPENIA IN PATIENTS BEING TREATED WITH LENALIDOMIDE plus DEXAMETHASONE FOR RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR-MM)

Leleu, X, Terpos, E, Sanz, RG, Cooney, J, OxxxGorman, P, Minarik, J, Greil, R, Williams, C, Gray, D, Szabo, Z HAEMATOLOGICA. 2014, 99: 368-368.

A PHASE II STUDY OF RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA)

Raderer, M, Kiesewetter, B, Willenbacher, W, Neumeister, P, Fridrik, M, Greil, R HAEMATOLOGICA. 2014, 99: 226-226.

UPDATED REPORT OF THE AUSTRIAN CML REGISTRY

Schmidt, S, Sill, H, Greil, R, Burgstaller, S, Schlogl, E, Petzer, A HAEMATOLOGICA. 2014, 99: 341-341.

Malignant Lymphoblasts in T Cell Acute Lymphoblastic Leukemia Express High Levels of Kv1.3

Groessinger, E, Weiss, L, Chen, MY, Wulff, H, Greil, R, Kerschbaum, H BIOPHYS J. 2014, 106(2): 551A-551A.

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.

Kubicka, S, Greil, R, Andre, T, Bennouna, J, Sastre, J, Van Cutsem, E, Von Moos, R, Osterlund, PJ, Hegde, P, Sersch, MA, Osborne, S, Hermann, F, Arnold, D J CLIN ONCOL. 2014, 32(3):

Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.

Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S, Hauser-Kronberger C, Ulmer H, Greil R. Int J Oncol. 2014 Jan,44(1):319-26. doi: 10.3892/ijo.2013.2176. Epub 2013 Nov 15.

Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.

Gampenrieder SP, Romeder F, MuГџ C, Pircher M, Ressler S, Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, Greil R. Anticancer Res. 2014 Jan,34(1):227-33.

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.

Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, et al. Ann Oncol. 2014 Feb,25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16.

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, WeiГџmann A, Adam Z. Blood. 2014 Feb 13,123(7):985-91. doi: 10.1182/blood-2013-08-521468. Epub 2013 Nov 13.